Comparison of Therapeutic G-CSF Cycles and Prophylactic G-CSF Cycles in Patients Receiving Paclitaxel and Carboplatin Combination Chemotherapy for Ovarian Cancer: A Retrospective Study Report
10.2185/jrm.2889
- Author:
Masaaki Kawashima
;
Hajime Kondo
- Publication Type:Journal Article
- Keywords:
granulocyte-colony stimulating factor (G-CSF);
ovarian cancer;
paclitaxel and carboplatin combination chemotherapy
- From:Journal of Rural Medicine
2014;9(2):86-89
- CountryJapan
- Language:English
-
Abstract:
Objective: The aim of the present study was to investigate the differencesbetween therapeutic granulocyte-colony stimulating factor (G-CSF) cycles and prophylacticG-CSF cycles in patients receiving paclitaxel and carboplatin combination chemotherapy forovarian cancer.
Material and Method: Medical records of 15 women who received paclitaxel andcarboplatin combination chemotherapy for ovarian cancer between January 2003 and December2012 were analyzed retrospectively. All 15 patients completed 6 cycles of paclitaxel andcarboplatin as the first-line chemotherapy. The complications were compared betweentherapeutic G-CSF cycles and prophylactic G-CSF cycles.
Results: The number of chemotherapy cycles correlated with the ratio ofprophylactic G-CSF cycles. It was considered that earlier prophylactic G-CSF injectionswere chosen due to a gradual decrease in WBC and neutrophil counts. The WBC and neutrophilcounts were significantly higher in prophylactic G-CSF cycles than in therapeutic G-CSFcycles. However, there were no significant differences in the intervals of chemotherapy,delay of chemotherapy, and incidence of febrile neutropenia between the therapeutic G-CSFand prophylactic G-CSF cycles.
Conclusion: Prophylactic G-CSF injections were not effective in preventingthe incidence of febrile neutropenia in patients receiving paclitaxel and carboplatincombination chemotherapy for ovarian cancer.
